Synlogic develops medicines using probiotic engineering to treat inborn errors of metabolism, immunomodulation, and metabolic diseases.

Synlogic plans to initiate phase 1b/2a studies in 2018 for hyperammonemia and phenylketonuria.

Additional data supporting the use of preclinical indications is ongoing.

Innovative biotechnology, collaborations with large pharma, insider/institutional buying, high cash reserve, and low valuation bode well for significant share price appreciation going forward.